

CPAP治療による心血管系の有益性はない (Abstract 2224)

SAVE: 冠動脈疾患患者に対するCPAP治療の心血管系への有益性は疑問である

SAVE: Cardiovascular benefit to CPAP treatment questioned in patients with coronary artery disease

冠動脈疾患および閉塞性睡眠時無呼吸を有する高齢者に対し、持続性陽圧気道 (CPAP) を用いた3年以上の夜間治療は、通常治療に比べ心血管系リスクをさらに軽減することはなかった。しかし重要なことに、CPAPは日中の眠気、健康関連QOL、気分—特に抑うつ症状—および出勤で定義された参加者のウェルビーイングを改善した。参加者は主に高齢者 (約61歳)、過体重、習慣性いびき症の男性で、全員が冠動脈疾患または脳血管疾患を有していた。このSAVEスタディの結果は2016年ESC Congressで発表され、同時に *New England Journal of Medicine* に掲載された。

Full Text

More than 3 years of nightly treatment with a continuous positive airway pressure (CPAP) machine did not reduce cardiovascular risk more than usual care among elderly patients with coronary artery disease and obstructive sleep apnea (OSA).

Findings from the Sleep Apnea Cardiovascular Endpoints (SAVE) study were presented at ESC Congress 2016, with simultaneous publication in the *New England Journal of Medicine*.

"Given the level of risk of cardiovascular disease attributed to OSA in previous observational studies, we were surprised not to find a benefit from CPAP treatment," said the study's principal investigator Doug McEvoy, MD, from the Adelaide Institute for Sleep Health at Flinders University in Adelaide, Australia.

The SAVE study recruited sleep apnea patients with moderate-to-severe disease from 89 clinical centers in 7 countries.

Participants were predominantly elderly (approximately 61 years), overweight, habitually snoring males – all with coronary artery or cerebrovascular disease.

A total of 2,717 individuals were randomized to receive usual care alone, or usual care plus CPAP.

To be eligible, participants had to achieve a minimum 3 hours of sham-CPAP adherence per night in a one week run-in before the study started.

Usual care included concomitant CV risk management, based on national guidelines, as well as advice on healthy sleep habits and lifestyle changes to minimize OSA.

The study showed that 42% of patients assigned to CPAP had good adherence (an average of 4 or more hours per night). Mean apnea-hypopnea index (AHI, a measure of OSA severity) decreased from 29.0 to 3.7 events per hour when patients used CPAP, indicating good control of their OSA.

However, after a mean follow-up time of 3.7 years for 1,341 usual care and 1,346 CPAP patients included in the final analysis, there was no difference between groups in the primary outcome – a composite of death from any CV cause, myocardial infarction or stroke, and hospitalization for heart failure, acute coronary syndrome, or transient ischemic attack.

Specifically, 17.0% of patients in the CPAP group and 15.4% in usual-care had a serious CV event (hazard ratio 1.10; 95% CI 0.91 to 1.32; P=0.34).

"It's not clear why CPAP treatment did not improve CV outcomes," said Prof McEvoy.

"It is possible that, even though the average CPAP adherence of approximately 3.3 hours per night was as expected, and more than we estimated in our power calculations, it was still insufficient to show the hypothesized level of effect on CV outcomes."

Importantly though, CPAP did improve the wellbeing of participants, defined by symptoms of daytime sleepiness, health-related quality of life, mood – particularly depressive symptoms – and attendance at work.

Prof. McEvoy said that "While it is disappointing not to find a reduction in CV events with CPAP treatment, our results show that treatment of OSA in patients with CV disease is nevertheless worthwhile – they are much less sleepy and depressed, and their productivity and quality of life is enhanced."

"More research is needed now on how to reduce the significant risk of CV events in people who suffer from sleep apnea," he added.

"Given our finding of a possible reduction in cerebrovascular events in patients who were able to use CPAP for more than 4 hours per night, and of prior studies showing a stronger association between OSA and stroke than between OSA and coronary artery disease, future trials should consider targeting patients with OSA and stroke who can achieve a high level of compliance with CPAP."

The study was funded by the National Health and Medical Research Council (NHMRC) of Australia, Philips Respironics Foundation, and others.

Dr. McEvoy reports research equipment grants from ResMed and Air Liquide, speaker fees from Philips Respironics, and holds a Practitioner Fellowship and other grants from the NHMRC.

Conference News

[News 01]

新規経口抗凝固薬はワルファリンと比べても遜色はない

[News 02]

Nebivololはアントラサイクリン毒性を予防する

[News 03]

非虚血性心不全におけるICDの延命効果は示されなかった

[News 04]

N-アセチルシステインはMI後の状態を引き上げる

[News 05]

CPAP治療による心血管系の有益性はない

[News 06]

幹細胞静脈内投与の期待されるベネフィット

[News 07]

心臓再生療法のトライアルが新たな知見をもたらす

[News 08]

短期間の抗血小板薬2剤併用療法は有効である

[News 09]

除細動前の抗凝固薬による新たな治療選択肢

[News 10]

冠動脈分岐部病変に対するステント留置技術の比較

[News 11]

STEMIにおいてプラスグレルとticagrelorの有効性は同等である

[News 12]

機能的画像検査の広範な使用が推奨される

[News 13]

アリロクマブは家族性高コレステロール血症のアフェレーシスを減少させる

[News 14]

伏在静脈グラフトにおいて薬剤溶出ステントはより有効である

[News 15]

光干渉断層法による有益性は小さい

[News 16]

抗凝固薬による出血に対する迅速かつ有効な中和剤